Erasca (NASDAQ: ERAS) faces a securities class action alleging executives misled investors about ERAS-0015's safety profile and intellectual property position. Shares plunged 54 percent over two trading days after disclosures about a patient death and a patent dispute with Revolution Medicines. The lead plaintiff deadline is Aug. 10, 2026.
Hagens Berman opened a securities fraud investigation into Erasca after ERAS shares plunged 54 percent on ERAS-0015 safety and patent disclosures.
"We're investigating whether Erasca may have intentionally misled investors about ERAS-0015's safety profile and about a potential moat in its particular, highly competitive cancer treatment space," Reed Kathrein, partner at Hagens Berman, said.
The class action covers investors who purchased Erasca securities between Jan. 14, 2025 and Apr. 26, 2026. On Apr. 27, Erasca disclosed in a Form 8-K that it received a letter from Revolution Medicines' legal counsel alleging ERAS-0015 infringes U.S. Patent No. 12,409,225 and involves trade secret misappropriation. Shares fell $2.34, or 10.9 percent, to $19.15. That evening, Erasca reported preliminary Phase 1 data showing one patient died from a Grade 3 treatment-related adverse event of pneumonitis that progressed to Grade 5, and acknowledged its prior comparisons to RMC-6236 were "not based on any head-to-head clinical trials." Shares fell another $9.25, or more than 45 percent, to $9.90 on Apr. 28, wiping out over $2.8 billion in market capitalization.
The complaint alleges Erasca and its executives violated federal securities laws by touting ERAS-0015 as a "best-in-class" pan-RAS molecular glue while failing to disclose that its preclinical data relied on improper comparisons to Revolution Medicines' RMC-6236, placing the company at risk of patent and trade secret violations. The company lacked a reasonable basis for its positive statements about ERAS-0015 throughout the class period, the complaint states.
Multiple firms are pursuing claims. Faruqi & Faruqi, LLP and Schall, Brown & Schwartz LLP have also filed or are investigating similar actions. Josh Wilson, securities litigation partner at Faruqi & Faruqi, is encouraging affected investors to contact the firm directly. The court-appointed lead plaintiff will be the investor with the largest financial interest in the relief sought who is adequate and typical of class members.
The lead plaintiff deadline is Aug. 10, 2026. Investors who purchased ERAS securities during the class period and suffered losses may seek appointment through counsel of their choice, or remain absent class members and still share in any recovery. Whistleblowers and former employees with information about Erasca's conduct are also encouraged to come forward.
The lawsuit's outcome could affect Erasca's ability to raise capital and advance ERAS-0015 through clinical development. Investors will watch for the lead plaintiff appointment and any further disclosures regarding the Revolution Medicines patent dispute.
This article is for informational purposes only and does not constitute investment advice.
